Detalhe da pesquisa
1.
CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer.
Br J Cancer
; 128(2): 331-341, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36385556
2.
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer.
J Transl Med
; 21(1): 843, 2023 11 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37996891
3.
Identification of spatially-resolved markers of malignant transformation in Intraductal Papillary Mucinous Neoplasms.
Nat Commun
; 15(1): 2764, 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38553466